Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Redx Pharma said that it and partner Medicines Discovery Catapult had been awarded UK government grant funding to cover the development of a panel of translational biomarkers.
The biomarkers would assess novel therapeutics in idiopathic pulmonary fibrosis, a life-threatening fibrotic lung condition.
The total grant awarded to fund the project was £515,595.
At 9:24am: (LON:REDX) Redx Pharma Plc share price was +0.25p at 7.25p